Acadia Pharmaceuticals
ACAD
193 hedge funds and large institutions have $3.17B invested in Acadia Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 65 increasing their positions, 63 reducing their positions, and 23 closing their positions.
52% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 23
42% more call options, than puts
Call options by funds: $45.7M | Put options by funds: $32.2M
6% more funds holding
Funds holding: 182 → 193 (+11)
4% more capital invested
Capital invested by funds: $3.06B → $3.17B (+$115M)
3% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 63
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$128M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$72.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$42.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$25.9M |
| 5 |
HM
HealthCor Management
New York
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$93.9M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$46.7M |
| 3 |
Alkeon Capital Management
New York
|
-$41M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$31.1M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$27.4M |
ACAD Hedge Fund Activity: Q1 2015 in Review
193 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2015, worth a combined $3.17B — up 3.8% from $3.06B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ACAD positions and 23 closed out — a net gain of 12 holders — while 65 added to existing stakes and 63 trimmed.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $128M. The largest seller was Viking Global Investors, exiting entirely with an estimated $93.9M sold.
- 193 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2015, up from 182 in Q4 2014.
- Funds reported $3.17B of Acadia Pharmaceuticals stock for Q1 2015, up 3.8% quarter-over-quarter.
- 35 funds opened new Acadia Pharmaceuticals positions in Q1 2015 and 23 closed out, a net change of +12 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2015 was OppenheimerFunds, an estimated $128M added.
- The largest Acadia Pharmaceuticals seller in Q1 2015 was Viking Global Investors, an estimated $93.9M sold.
Based on aggregated 13F filings for Q1 2015.